Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed. Eligible patients had received ≥ 1 line of treatment an...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2020-08, Vol.20 (8), p.509-518
Hauptverfasser:	Mateos, Maria-Victoria, Sonneveld, Pieter, Hungria, Vania, Nooka, Ajay K., Estell, Jane A., Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Medvedova, Eva, Weisel, Katja, Chiu, Christopher, Schecter, Jordan M., Amin, Himal, Qin, Xiang, Ukropec, Jon, Kobos, Rachel, Spencer, Andrew
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trial Efficacy Minimal residual disease Relapsed/refractory Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!